Answer to dengue and chikungunya: specific antiviral therapy

Authors

  • Mrinmay Ghosh Professor, Department of Medicine, Katihar Medical College, Katihar - 854105, Bihar, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20171069

Abstract

Dengue is probably the most important arthropod borne viral disease worldwide, with 50-100 million infections occurring per year. Year-round transmission of dengue viruses of serotype 1-4 is prevalent globally. Vectors are Aedes aegypti and Aedes albopictus. Laboratory diagnosis by ELISA for IgM or RT-PCR, Incubation period 4-7days, sudden onset of fever, frontal headache, retro orbital pain, back pain with severe myalgia, a transient macular rash on the first day, lymphadenopathy, palatal vesicles, scleral infections. Illness may last a week with clinical signs; anorexia, nausea, vomiting, marked cutaneous maculopapular rash on trunks spreading to extremities and face on defervescences on days 3-5. Epistaxis, scattered petechiae and preexisting gastrointestinal lesions may bleed during acute phase.

References

Harrison's Principles of Internal Medicine, Nineteenth Edition, Pub. Mc Graw Hill; 2015:1318-1319.

Current Medical Diagnosis and Treatment: Pub. Mc Graw Hill; 2014:1340.

Manson's Tropical Diseases, Ed. 23rd, Pub. ELSEVIER, Saunders; 2014:162-70.

Hardman JG, Limbard LE. Ribavarin inhibits the replication of wide range of RNA and DNA viruses including orthomyxo, paramyxo, arena, bunya, flavi, hepres, adeno, pox and retroviruses. Goodman & Gilman's: the pharmacological basis of therapeutics. 10th Ed. Mcgraw Hill. 2001;1336-37.

Tam RC, Lau JY, Hong Z. Mechanism of action of Ribavirin in antiviral therapies. Antiviral Chemother. 2002;12:261-72.

Goodman and Gilman's: The Pharmacological Basis of Therapeutics, Eds: Joel G. Hardman, Lee E. Limbard, Tenth Edition Pub. Mc. Graw Hill; 2001:1336-7.

Downloads

Published

2017-03-23